

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-25 (Canceled)

Claim 26 (Currently Amended)      A method for producing an immune response against HIV-1 infection in a human comprising the steps of:

- (1) administering to the human an immunogenic composition comprising an intranasal or an intramuscular dosage of a recombinant adenovirus comprising an expression cassette containing a promoter, a nucleic acid sequence encoding the HIV-1 gp160 or gp120 polypeptide sequence and a polyadenylation signal sequence and
- (2) administering to the human one or more intranasal or intramuscular booster dosages of the recombinant adenovirus.

Claim 27 (Canceled)

Claim 28 (Currently Amended)      The method of claim ~~27~~ 26, wherein the administering one or more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof.

Claim 29 (Previously presented)      The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus.

Claim 30 (Previously presented)      The method of claim 26, wherein the expression cassette further comprises the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 or gp120 sequence and before the polyadenylation signal sequence.

Claim 31 (Previously presented) The method of claim 26, wherein the HIV-1 gp160 sequence is the MN strain gp160 sequence or the LAV strain gp160 sequence.

Claim 32 (Previously presented) The method of claim 26, wherein the HIV-1 gp160 sequence is replaced by a sequence encoding the gag-pro region of HIV-1.

Claim 33 (Previously presented) The method of claim 26, wherein the intranasal dosage is about  $1 \times 10^7$  pfu of virus.

Claim 34 (Previously presented) The method of claim 26, wherein the intramuscular dosage is in the range of  $1 \times 10^7$  to  $2 \times 10^9$  pfu of virus.

Claim 35 (Currently Amended) The method of claim ~~27~~ 26, wherein the intranasal booster dosage is in the range of  $1 \times 10^7$  to  $1 \times 10^8$  pfu of virus.

Claim 36 (Currently Amended) The method of claim ~~27~~ 26, wherein the intramuscular booster dosage is in the range of  $1 \times 10^{10}$  to  ~~$8 \times 10^8$~~   $8 \times 10^{10}$  pfu of virus.

Claim 37 (Previously presented) The method of claim 28, wherein the antigen polypeptide dosage comprises between 200  $\mu$ g and 0.5 mg of antigen polypeptide.

Claim 38 (Previously presented) The method of claim 26, wherein the adenovirus comprises a deletion in the E3 gene.

Claim 39 (Currently Amended) The method of claim 26, wherein the adenovirus comprises a deletion in the E3 gene and a deletion in the E1 gene ~~or the E5 gene~~.

Claim 40 (Previously presented) The method of claim 26, wherein the adenovirus comprises a deletion in the E1 gene.

Claim 41 (Canceled)